Cannabis vapor shows real relief in gold-standard migraine study

This groundbreaking study represents the first randomized, double-blind, placebo-controlled trial examining vaporized cannabis for acute migraine treatment. Researchers recruited patients experiencing active migraine attacks and had them inhale either vaporized cannabis flower or a matching placebo. The study used a crossover design, meaning participants tried both treatments on separate occasions, allowing each person to serve as their own control. The cannabis used contained both THC and CBD, mimicking real-world cannabis products available to patients.

The results showed that vaporized cannabis significantly reduced migraine pain intensity compared to placebo within two hours of administration. Participants reported meaningful improvements in pain scores, and the treatment was generally well-tolerated with manageable side effects. This study provides crucial clinical evidence that cannabis may be an effective acute treatment option for migraine sufferers, addressing a significant gap in scientific literature. While previous surveys and observational studies suggested cannabis helped migraines, this rigorous controlled trial offers the gold-standard evidence needed to validate patient experiences and guide clinical recommendations.